DeepUll key facts
as of Oct 2026- Operator of a biotechnology company intended to offer an early diagnosis of sepsis and therapeutic recommendations.
- DeepUll is valued at approximately $26.0M as of Oct 2026 (last reported valuation).
- It has raised $91.3M; the latest was Later Stage VC ($50.0M) in Apr 2025.
- Notable investors include UI Investissement, Kurma Partners, CDTI Innvierte, Panakes Partners, Asabys Partners — 15 tracked in total.
- Status: Privately Held (backing).
DeepUll's last reported valuation, Oct 2022. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch DeepUll: the Monday email on marks, rounds and moves
DeepUll funding rounds
No funding rounds for DeepUll are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs DeepUll
15+DeepUll valuation
DeepUll's last reported valuation was $26 million in Oct 2022. No priced round, secondary trade or fund mark has surfaced since.
DeepUll investors
15 investors are on record for DeepUll, including UI Investissement, Kurma Partners, CDTI Innvierte and Panakes Partners. By type, the record holds 3 venture capital firms, 1 family office and 1 private equity firm.
About DeepUll
Operator of a biotechnology company intended to offer an early diagnosis of sepsis and therapeutic recommendations. The company uses artificial intelligence to identify the causative infective agent and provide phenotypic antimicrobial susceptibility results, reducing the unnecessary use of antimicrobials and developing a new diagnostic system that will detect pathogens and antibiotic resistance, without a prior cultivation stage, enabling patients to get treated in the early stages of the disease.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2019
- Employees
- 41
- Website
- deepull.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.